Is CANTA.ST overvalued or undervalued?

CANTA.ST currently has a P/E ratio of 2.01. Relative to the sector average of 36.50, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Cantargia AB (publ) stock?

Cantargia AB (publ) trades on STO. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of CANTA.ST?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying CANTA.ST protect my money against local inflation?

Many investors in Latin America buy international stocks like CANTA.ST to protect their purchasing power. Because CANTA.ST is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy CANTA.ST shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is CANTA.ST a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well CANTA.ST diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksCANTA.ST

Cantargia AB (publ)

kr 1.37+kr 0.04+3.01%

STO / SEK

Market cap

kr 386M

P/E

2.0

EPS (TTM)

kr 0.07

Dividend yield

0.00%

Beta

1.59

1Y return

-47.31%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$02021

$02022

$02023

$02024

$34M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity—
Current ratio7.03
Cash ratio4.84
Net margin52.8%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

CANTA.ST2.0
Healthcare sector median36.5
S&P 50022.0

Trades about 94% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.01
Price to book1.29
EPS (TTM)kr 0.07
Payout ratio0%
FCF yield14.40%

Range & risk

kr 1.31kr 6.59

Trading in the lower third of its 52-week band

Beta1.59

Profile

What Cantargia AB (publ) actually does

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.

CEO

Hilde Hermansen Steineger

Employees

Headquarters

Lund, SN

Founded

2015-03-17

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save CANTA.ST and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

CANTA.ST has a beta of 1.59, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Cantargia AB (publ)